Human Molecular Genetics, Vol 3, 1497-1502, Copyright © 1994 by Oxford University Press
WK O'Neal and AL Beaudet
There is considerable potential to ameliorate the pulmonary disease in
cystic fibrosis (CF) using somatic gene therapy. Even low levels of
expression of the gene in airways epithelium may be beneficial. Adenoviral
vectors, DNA-liposome complexes, adeno-associated viral vectors and
DNA-ligand complexes have been used effectively in vitro and have been
tested in animals to varying extent. Adenoviral vectors and DNA-liposome
complexes are being used to deliver the CF gene to patient airways in phase
I clinical trials. Transient correction of the electrophysiological defect
in human CF nasal epithelium has been achieved. Major goals are (i) to
demonstrate that expression of the CF gene in airways epithelium will
ameliorate lung disease in CF patients, and (ii) to achieve long-term
expression of the introduced gene either through a single delivery with
persistent expression or through the ability to use a delivery system
repetitively with safety and efficacy.
REVIEWS
Somatic gene therapy for cystic fibrosis
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77020.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. R. Broughman, R. M. Brandt, C. Hastings, T. Iwamoto, J. M. Tomich, and B. D. Schultz Channel-forming peptide modulates transepithelial electrical conductance and solute permeability Am J Physiol Cell Physiol, June 1, 2004; 286(6): C1312 - C1323. [Abstract] [Full Text] [PDF] |
||||
